Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer

Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer

In recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC), survival outcomes are significantly better in patients who receive anti-programmed cell death-1 (PD-1) monoclonal antibody therapy than in those who receive standard therapy. However, there is no established biomarker that...

Full description

Bibliographic Details
Main Authors: Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Teruyuki Higa, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Masatomo Toyama, Tomoyo Higa, Hidetoshi Kinjyo, Norimoto Kise, Shunsuke Kondo, Hiroyuki Maeda, Taro Ikegami
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Current Oncology
Subjects:
anti-programmed cell death-1 antibody
programmed cell death ligand-1
polymorphism
nutrition
head and neck cancer
immune-related adverse events
Online Access:https://www.mdpi.com/1718-7729/30/6/410

Internet

https://www.mdpi.com/1718-7729/30/6/410

Similar Items